LiverLearning®

Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • HBV - Update on the Guidelines and Controversies in Management

    Product not yet rated Contains 1 Component(s) Recorded On: 10/24/2018

    Webinar hosted by the Hepatitis B Special Interest Group October 24, 2018.

    This webinar focuses on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk.  The second presentation addresses a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.

    Marc G. Ghany (Moderator)

    Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

     

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Kosh Aggarwal

    Dr. Kosh Agarwal is a Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies, King’s College Hospital. Dr Agarwal is the Lead for the Kings Viral Hepatitis Service, the largest treatment centre for viral hepatitis in the UK. In 1991 Dr Agarwal graduated from Newcastle University and his postgraduate training was undertaken in Newcastle with the majority of his clinical and research training at the Regional Liver and Transplant Unit. Prior to his appointment at King’s, Dr Agarwal was a consultant and honorary senior lecturer at the Regional Liver and Transplant Unit in Newcastle. He also spent a year at the Division of Liver Diseases, Mount Sinai, New York, USA. Dr Agarwal is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic Hepatitis B and C. He is a member of the EASL, AASLD, BASL, & ILTS.

  • Maintenance of Certification (MOC) 2018 Postgraduate Course

    Contains 3 Component(s), Medical Credits Offered

    Claim your Maintenance of Certification (MOC) points for the Postgraduate Course from The Liver Meeting® 2018.

    This is the MOC evaluation for the attendees of the live 2018 Postgraduate Course held Saturday, November 10 from 8:00 am – 5:00 pm at The Liver Meeting® in San Francisco, California. Those that do not attend the live course but are AASLD members or LiverLearning® subscribers will be able to access the 2018 Postgraduate Course Enduring Activity which will include recordings of all of the sessions and the MOC quizzes (see release dates below). Those that attended the live course must complete their CME evaluation prior to claiming MOC through The Liver Meeting® evaluation within The Liver Meeting® app or  on AASLD's online CME claiming page.

    2018 Postgraduate Course Enduring Release Dates:

    • The Liver Meeting® 2018 Attendees: Immediately following The Liver Meeting®
    • AASLD Members: February 1, 2019
    • LiverLearning® Subscribers: March 1, 2019

    Speakers

    • Michael W. Fried, MD, FAASLD (Program Chair)
    • Cynthia Levy, MD, FAASLD (Program Chair)
    • Tse-Ling Fong, MD, FAASLD (Program Chair)
    • Naga P. Chalasani, MD, FAASLD (Moderator)
    • Rohit Loomba, MD (Moderator)
    • Alfred Sidney Barritt, MD, MSCR
    • Michael P. Manns, MD
    • Heiner Wedemeyer, MD
    • Mandana Khalili, MD
    • Guadalupe Garcia-Tsao, MD, FAASLD (Moderator)
    • Oren K. Fix, MD, MSc, FAASLD (Moderator)
    • Kymberly Watt, MD
    • Andres Cardenas, MD, MMSc, PhD, FAASLD
    • Steven L. Flamm, MD
    • Rajiv Jalan, MD, PhD, FRCP, FRCPE, FAASLD
    • Vijay Shah, MD
    • Laura M. Kulik, MD (Moderator)
    • K. Rajender Reddy, MD, FAASLD (Moderator)
    • Christopher L. Bowlus, MD, FAASLD
    • Paul Y. Kwo, MD, FAASLD
    • Lewis R. Roberts, MBChB, PhD, FAASLD
    • Paul C. Adams, MD, FAASLD
    • Mindie H. Nguyen, MD, MAS, FAASLD
    • Robert S. Brown, MD, MPH, FAASLD (Moderator)
    • Estella M. Alonso, MD, FAASLD (Moderator)
    • Nancy Reau, MD, FAASLD
    • Keyur Patel, MD
    • Michael B. Fallon, MD, FAASLD
    • Elizabeth Rand, MD
    • Patrick S. Kamath, MD

    Session I: Morning Routine

    MODERATORS: Naga P. Chalasani, MD, FAASLD and Rohit Loomba, MD

    8:00 - 8:10 AM                                                                   A Hectic Day in the Life of a Hepatology Consultant

                                                                                                    Welcome/Qualities of a Valued Consultant

    8:10 - 8:30 AM                                                                   Abnormal Liver Enzymes in a Patient with Diabetes

                                                                                                    Alfred Sidney Barritt, MD, MSCR

    8:30- 8:50 AM                                                                    Hepatitis C in a 23-year-old who Injects Drugs

                                                                                                    Michael P. Manns, MD

    8:50 - 9:10 AM                                                                   Abnormal Liver Enzymes and Recurrent UTI in a 67-year-old Woman

                                                                                                    Heiner Wedemeyer, MD

    9:10 – 9:30 am                                                                  HBV/HCV Coinfection in a Pregnant Woman

                                                                                                    Mandana Khalili, MD

    9:30 – 9:50 am                                                                  Break

    Session II: Rounds in the MICU

    MODERATORS: Guadalupe Garcia-Tsao, MD, FAASLD and Oren K. Fix, MD, MSc, FAASLD 

    9:50 - 10:10 AM                                                                Fever and Elevated Liver Enzymes in a Liver Transplant Recipient

                                                                                                    Kymberly Watt, MD

    10:10 - 10:30 AM                                                              Massive GI Bleeding in a Patient with Cirrhosis: What’s New?

                                                                                                    Andres Cardenas, MD, MMSc, PhD, FAASLD

    10:30 - 10:50 AM                                                              Altered Mental Status in a Patient with Refractory Ascites

                                                                                                    Steven L. Flamm, MD

    10:50 – 11:10 AM                                                             Acute Liver Failure in a 26-year-old Woman

                                                                                                    Rajiv Jalan, MD, PhD, FRCP, FRCPE, FAASLD

    11:10 - 11:30 AM                                                              Jaundice and Renal Failure in a Patient with Alcoholic Cirrhosis

                                                                                                    Vijay Shah, MD

    11:30 - 11:40 AM                                                              Break

    11:40 - 1:05 PM                                                                Intermission/Meet-the-Professor Luncheons

    Session III: Meanwhile, Back in the Office…

    MODERATORS: Laura M. Kulik, MD and K. Rajender Reddy, MD, FAASLD

    1:05 - 1:25 PM                                                                   Cholestatic Liver Abnormalities in a 52-year-old African American Woman

                                                                                                    Christopher L. Bowlus, MD, FAASLD

    1:25 – 1:45 pm                                                                  Multiple Liver Masses in a 42-year-old Woman Advances in the Diagnosis of Hepatobiliary Neoplasia

                                                                                                    Paul Y. Kwo, MD, FAASLD

    1:45 – 2:05 pm                                                                  A 1.9 cm HCC in a Patient with HCV Cirrhosis

                                                                                                    Lewis R. Roberts, MBChB, PhD, FAASLD

    2:05 – 2:25 pm                                                                  “My Brother Was Just Told He Had Too Much Iron in His Blood”

                                                                                                    Paul C. Adams, MD, FAASLD

    2:25 – 2:45 pm                                                                  A Patient with Crohn’s Disease and HBcAb+

                                                                                                    Mindie H. Nguyen, MD, MAS, FAASLD

    2:45 – 3:05 pm                                                                  Break

    Session IV: Exploring Other Units at Dusk

    MODERATORS: Robert S. Brown, MD, MPH, FAASLD and Estella M. Alonso, MD, FAASLD

    3:05 – 3:25 pm                                                                  Hyperbilirubinemia in Labor and Delivery

                                                                                                    Nancy Reau, MD, FAASLD

    3:25 – 3:45 pm                                                                  Hyperbilirubinemia in a Patient after Bone Marrow Transplant

                                                                                                    Keyur Patel, MD

    3:45 – 4:05 pm                                                                  A 60-year-old in CCU with Jaundice

                                                                                                    Michael B. Fallon, MD, FAASLD

    4:05 – 4:25 pm                                                                  A 14-year-old Child s/p Fontan Procedure with Liver Abnormalities

                                                                                                    Elizabeth Rand, MD

    4:25 – 4:45 pm                                                                  Acute Right Upper Quadrant Pain in a Patient with Cirrhosis

                                                                                                    Patrick S. Kamath, MD

    4:45 – 5:00 pm                                                                 Wrap Up

    Upon completion of this activity, participants will be able to:

    • Differentiate presentations of complex liver diseases across different patient populations
    • Apply best practices to diagnose and manage inpatients and outpatients with complex liver disease
    • Communicate therapeutic recommendations to multiple healthcare providers encompassing the extended care team

    Hepatologists   

    Gastroenterologists       

    Nurses

    Nurse Practitioners        

    Pharmacists

    Physician Assistants       

    Transplant Coordinators

    Surgeons            

    Fellows/Trainees

    Participants must complete the CME evaluation <link> for this course and pass this MOC evaluation with a score of 70% or higher to receive MOC points.  If you are seeking continuing education credit or MOC points for a specialty other than ABIM or ABP, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.   

    This activity was planned in the context of the following ACGME/IOM/IPEC competencies: Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Interpersonal and Communication Skills, Professionalism, Systems-based Practice, Provide Patient-centered care, Work in Interdisciplinary Teams, Employ Evidence-based practice, Apply Quality Improvements, Utilize Informatics, Values/Ethics for Interprofessional Practice, Roles/Responsibilities, Interprofessional Communication, Teams and Teamwork.

    Continuing Medical Education (CME) Statement

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Association for the Study of Liver Diseases (AASLD) designates this live activity for a maximum of 6.75 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification

    American Board of Internal Medicine (ABIM) MOC Statement

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Pediatrics (ABP) MOC Statement

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participation and feedback to the participant, enables the participant to earn 6 MOC points in the American Board of Pediatrics (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    Successful completion for ABIM and ABP MOC points is defined as having completed the following elements:

    • Attended the 2018 Postgraduate Course 
    • Claimed CME for the 2018 Postgraduate Course (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity. ABP Rule: Must complete full activity and claim full amount of CME credits.)
    • Completed the MOC evaluation for the 2018 Postgraduate Course

    DEADLINE: Be sure to complete the MOC evaluation for points before the following dates:

    • For ABIM points to be submitted for 2018, you must complete evaluations no later than December 14, 2018. Evaluations completed after that date may not be submitted until 2019.
    • For ABP points to be submitted for 2018, you must complete evaluations no later than December 1, 2018 as ABP’s deadline is December 1. Evaluations completed after that date will continue to be submitted but may not be credited until 2019.
    • MOC evaluations will remain available until March 15, 2019. Requests for MOC after this date will not be honored.
    • Note: AASLD submits MOC points on behalf of its learners to ABIM and ABP. Points are not submitted automatically and will not display immediately on your ABIM or ABP MOC Profile upon completion of the MOC evaluation. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.

    Faculty, Planner and AASLD Staff Disclosures

    This live educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the AASLD Postgraduate Course faculty and the following planning committees: AASLD Education Committee, Scientific Program Committee, and the Governing Board.

    As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months.  A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  All conflicts of interest are resolved prior to participation.

    Statement on off-label and investigational use: Speakers are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device. Financial disclosures will appear at the beginning of each session and are provided below:

    Postgraduate Course Faculty Disclosures

    Paul C. Adams, MD, FAASLD

    Consulting: Protagonist Therapeutics

    Alfred Sidney Barritt IV, MD, MSCR

    Advisory Committee or Review Panel: Target Pharmasolutions

    Consulting: Dova Pharmaceuticals

    Speaking and Teaching: SC Liver Research Consortium

    Christopher L Bowlus, MD, FAASLD

    Advisory Committee or Review Panel: BMS, Contatus, Cymabay

    Consulting: Eli Lilly, BiomX

    Grant/Research Support: TARGET Pharmasolutions, JKB Taiwan, Genkyotex, Takeda, Allergan, GSK, Arena, Gilead, Cymabay, Intercept Pharmaceuticals, Novartis, Eli Lilly

    Andres Cardenas, MD, MMSc, PhD, FAASLD

    Board Membership: Liver Transplantation Journal

    Consulting: UptoDate

    Grant/Research Support: Boston Scientifi

    Michael B. Fallon, MD, FAASLD

    Nothing to Disclose

    Steven L. Flamm, MD

    Consulting: Gilead, Abbvie, Merck, Salix, Intercept, Dova, Shonogi

    Grant/Research Support: Gilead, Abbvie, Intercept

    Rajiv Jalan, MD, PhD, FRCP, FRCPE, FAASLD

    Consulting: Yaqrt Ltd

    Grant/Research Support: Ocera Therapeutics Inc.

    Patrick S Kamath, MD

    Nothing to Disclose

    Mandana Khalili, MD

    Grant/Research Support: Gilead Sciences, Intercept Pharmaceuticals

    Paul Yien Kwo, MD, FAASLD

    Advisory Committee or Review Panel: Abbvie, BMS, Gilead, Merck, Shionogi, Dova, Durect, Janssen

    Grant/Research Support: Abbvie, Gilead, Aurora, La Jolla Pharmaceuticals

    Speaking and Teaching: Merck

    Stock Shareholder: Durect

    Michael P. Manns, MD

    Advisory Committee or Review Panel: MSD - Merck Sharp & Dome, Abbvie, Novartis, Gilead, Bristol-MyersSquibb

    Consulting: AbbVie, Gilead, Curevac, Eiger, Enyo Pharma, Falk Foundation, Intercept, Janssen, Medgenics, MSD - Merck, Novartis, GedeonRichter, Roche, Allergan, Preglem

    Grant/Research Support: AbbVie, Gilead, Eiger, Intercept, J

    Mindie H. Nguyen, MD, MAS, FAASLD

    Advisory Committee or Review Panel: Gilead

    Consulting: Spring Bank, Norvatis

    Grant/Research Support: Gilead, B K Kee Foundation, NCI

    Keyur Patel, MD

    Advisory Committee or Review Panel: Gilead Sciences, Merck

    Elizabeth Rand

    Nothing to Disclose

    Nancy Reau, MD, FAASLD

    Nothing to Disclose

    Lewis R. Roberts, MBChB, PhD, FAASLD

    Advisory Committee or Review Panel: Bayer, Exact Sciences, TAVEC, Inc

    Grant/Research Support: Gilead Sciences, Wake Diagnostics, Ariad Pharmaceuticals, BTG International, RedHill BioPharma

    Vijay Shah, MD

    Advisory Committee or Review Panel: Novartis Pharmaceuticals, Merck Research Laboratories, Afimmune, Ltd, Durect Corporation

    Kymberly Watt, MD

    Grant/Research Support: Gilead, Intercept

    Heiner Wedemeyer, MD

    Advisory Committee or Review Panel: Norgine, MSD, Janssen, Roche Diagnostic

    Board Membership: Abbvie, Gilead

    Consulting: Abbott, BMS, Eiger, MyrGmbH

    Grant/Research Support: Abbott, BMS, Gilead, Roche Diagnsotics

    Speaking and Teaching: Abbvie, Abbott, BMS, Gilead, Falk, Norgine, MSD

    Planner Disclosures

    Gavin E. Arteel, PhD, FAASLD (Scientific Program Committee)

    Nothing to Disclose

    Gyorgy Baffy, MD, PhD, FAASLD (Education Committee)

    Nothing to Disclose

    Jasmohan S. Bajaj, MD, MSc, FAASLD (Education Committee)

    Consulting: Valeant, Norgine, and Abbott

    Grant/Research Support: Salix, Grifols

    Ramon Bataller, MD, PhD (Education Committee)

    Speaking and Teaching: Echosens

    Alex Befeler, MD (Scientific Program Committee)

    Advisory Committees or Review Panels: Bayer, Gilead

    Grant/Research Support: Mallinckrodt, Sillajen

    Stock Shareholder: Amgen, Gilead

    Jorge A. Bezerra, MD, FAASLD (Education Committee and Governing Board)

    Grant/Research Support: Gilead, Molecular Genetics Laboratory, CHMC, Shier

    Kyle E. Brown, MD, FAASLD (Education Committee)

    Nothing to Disclose

    Kimberly A. Brown, MD, FAASLD (Governing Board and Scientific Program Committee)

    Advisory Committees or Review Panels: AbbVie, Bristol-Myers Squibb, CLDF, Gilead, Janssen, Merck

    Grant/Research Support: AbbVie, Duke medical research, Gilead, Janssen, Merck, Novartix

    Speaking and Teaching: CLDF

    Elizabeth M. Brunt, MD, FAASLD (Education Committee)

    Advisory Committees or Review Panels: Gilead

    Andres Cardenas, MD, PhD, FAASLD (Education Committee)

    Advisory Committees or Review Panels: Gilead

    Amanda J. Chaney, DNP, ARNP, FNP-BC (Education Committee)

    Nothing to Disclose

    Raymond T. Chung, MD, FAASLD (Governing Board)

    Advisory Committees or Review Panels: Alnylam

    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, Janssen, Merck

    Mark J. Czaja, MD, FAASLD (Governing Board)

    Consulting: Verlyx Pharma Inc.

    Michael W. Fried, MD, FAASLD (Governing Board and Scientific Program Committee)

    Consulting: AbbVie, Bristol-Myers Squibb, Gilead, Merck, TARGET PharmaSolutions

    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead, Merck

    Stock Shareholder: TARGET PharmaSolutions

    Julie Heimbach, MD, FAASLD (Governing Board)

    Nothing to Disclose

    Patrick M. Horne, MSN, ARNP, FNP-BC (Scientific Program Committee)

    Advisory Committees or Review Panels: AbbVie, Bristol-Myers Squibb, Chronic Liver Disease Foundation, Gilead Sciences, Merck

    Wikrom Karnsakul, MD (Education Committee)

    Nothing to Disclose

    Andrew P. Keaveny, MD, FAASLD (Education Committee and Scientific Program Committee)

    Independent Contractor: UpToDate Inc

    Cynthia Levy, MD (Scientific Program Committee)

    Advisory Committees or Review Panels: Target Pharmasolutions

    Board Membership: Liver Transplantation

    Consulting: Intercept, Novartis

    Grant/Research Support: CymaBay, Gilead, Intercept, NGM, Novartis, Tobira

    Speaking and Teaching: Medscape

    Keith D. Lindor, MD, FAASLD (Governing Board)

    Advisory Committees or Review Panels:  Intercept, Shire

    Anna S. Lok, MD, FAASLD (Governing Board and Scientific Program Committee)

    Grant/Research Support: Bristol-Myers Squibb, Gilead, Target Solutions

    Bruce A Luxon, MD, PhD, FAASLD (Governing Board)

    Nothing to Disclose

    John C. Magee, MD (Scientific Program Committee)

    Nothing to Disclose

    Mitchell A. Mah'moud, MD, FAASLD (Education Committee)

    Nothing to Disclose

    Richard A. Manch, MD, FAASLD (Education Committee)

    Speaking and Teaching:  Salix, Bayer, Gilead, AbbVie, Intecept

    Lopa Mishra, MD, FAASLD (Governing Board)

    Nothing to Disclose

    David C. Mulligan, MD, FAASLD (Education Committee)

    Nothing to Disclose

    Mary K. Panther, BSN, RN, CGRN (Education Committee)

    Stock Shareholder: Merck

    K. Gautham Reddy, MD, FAASLD (Scientific Program Committee)

    Advisory Committees or Review Panels: Gilead, Intercept

    Grant/Research Support: Genfit, Intercept, Merck

    Speaking and Teaching: Intercept

    Ronald J. Sokol, MD, FAASLD (Governing Board and Scientific Program Committee)

    Consulting: Alexion, Alnylam, Retrophin

    Grant/Research Support: FFF Enterprises, Giliad, Shire/Lumena

    Grace L. Su, MD, FAASLD (Education Committee)

    Nothing to Disclose

    Ayako Suzuki, MD, PhD, MSc (Education Committee)

    Nothing to Disclose

    Lisa B. VanWagner, MD, MSc (Education Committee)

    Grant/Research Support: Novartis

    Speaking and Teaching: Salix

    Steven A. Weinman, MD, PhD, FAASLD (Education Committee)

    Nothing to Disclose

    Maria L. Yataco, MD (Education Committee)

    Grant/Research Support: Genfit/Intercept

    AASLD Staff Disclosures

    Amy D'Amato

    Nothing to Disclose

    Katie Duggan

    Nothing to Disclose

    Steven Echard, IOM, CAE

    Nothing to Disclose

    Stephanie Grimsby

    Nothing to Disclose

    Jessica Jessop

    Nothing to Disclose

    Janeil C. Klett

    Nothing to Disclose

    Denise Seise

    Nothing to Disclose  

  • 2018 Transplant Hepatology Board Review Course

    Contains 36 Component(s), Medical Credits Offered Recorded On: 08/19/2018

    This course will help prepare physicians for the ABIM and ABP certification and MOC exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint.

    This course will help prepare physicians for the American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) certification and maintenance of certification (MOC) exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint. High yield clinical topics will be presented by leaders in the field of hepatology and transplant medicine. Designed for ABIM/ABP Transplant Hepatology exam preparation, the course also provides a comprehensive review of up-to-date management of liver transplant patients.

    Online Course Pricing:

    • Member — $325
    • Trainee and Associate Member — $185
    • Nonmember — $540
    • Nonmember Trainee / Associate — $235
    • Industry — $775

    Core Competencies

    • Patient care and Procedural Skills
    • Medical knowledge
    • Practice-based learning and improvement
    • Patient-centered care
    • Evidence-based practice
    • Quality improvement
    • Values/Ethics for inter-professional practice

    Program Chairs:

    • K. Gautham Reddy, MD, FAASLD
    • Oren K. Fix, MD, MSc, FAASLD
    • Laura M. Kulik, MD

    Components

    29 online interactive recorded sessions, 20-30 minutes in length
    Post-activity quiz for each session

    Release Date: September 14, 2018
    Expiration Date: September 13, 2020

    Copyright: All faculty in this activity have given their permission for publication OR ©2018 AASLD

    K. Gautham Reddy (Moderator)

    Oren K. Fix (Moderator)

    Laura M. Kulik (Moderator)

    Michael R. Lucey

    Julie Heimbach

    Michael R. Charlton

    Marina G. Silveira

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

    Philip Rosenthal

    Michael F. Chang

    Josh Levitsky

    Robert J. Fontana

    Jacquelyn F. Fleckenstein

    Steven L. Flamm

    Scott W. Biggins

    Carl L. Berg

    Sandy Feng

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Peter Chin-Hong

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Mark W. Russo

    Philip Rosenthal

    Andrew I. Aronsohn

    Lisa VanWagner

    Dr. Lisa VanWagner is an Assistant Professor of Medicine and Preventive Medicine in the Division Gastroenterology & Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.  She is board certified in Transplant Hepatology.  Her laboratory utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Her research group developed the first simple scoring model (CAR-OLT score) — accessible via web or smartphone apps — which enables healthcare providers, caregivers and patients to estimate 1-year risk for cardiovascular complications after liver transplantation.

    Upon completion of this activity, learners will be able to: 

    • Discuss the diagnosis, natural history, and therapies for liver diseases leading to liver transplantation;
    • Discuss the management of patients awaiting liver transplantation;
    • Discuss the immediate post-operative and long-term management of liver transplant recipients;
    • Discuss current organ allocation policy and its effects on selecting potential liver transplant recipients.


    • Hepatologists
    • Fellows/ Trainees

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.   

    CME 

    Accreditation Statement The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation AASLD designates this enduring activity for a maximum of 11.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Maintenance of Certification

    American Board of Internal Medicine (ABIM) MOC Statement 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Pediatrics (ABP) MOC Statement

    “Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 11.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”

    MOC Points Process

    Physicians seeking MOC points must complete the CME evaluation in addition to viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.


    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Andrew I. Aronsohn, MD
    Faculty
    Nothing to Disclose

    Carl L. Berg, MD, FAASLD
    Faculty Scientific
    Consulting: Dova Pharnaceuticals, Grifols

    Scott W. Biggins, MD, MAS, FAASLD
    Faculty
    Nothing to Disclose

    Michael F. Chang, MD, MSc
    Faculty
    Nothing to Disclose

    Michael R. Charlton, MD, FRCP
    Faculty
    Grant/Research Support: Intercept, GIlead Sciences, Merck, Janssen, AbbVie, Novartis Scientific
    Consulting: Gilead Sciences

    Peter Chin-Hong, MD
    Faculty
    Grants/Research Support: Karius

    Sandy Feng, MD, PhD
    Faculty
    Stock/Stock Options: Abbott, Charles River Labs, Eli Lily, Express Scripts, Glaxo-Smith Klein, Medco, Merck, Pfizer, Hospira, Amgen, Johnson & Johnson, Stryker
    Advisory Committees and/or Review Panels: Juno Therapeutics, Inc., American Journal of Transplantation, Immune Tolderance Network, OPTN/UNOS, The New England Journal of Medicine
    Grants/Research Support: Novartis, Quark

    Oren K. Fix, MD, MSc, FAASLD
    Faculty
    Nothing to Disclose

    Steven L. Flamm, MD
    Faculty
    Nothing to Disclose

    Jacquelyn F. Fleckenstein, MD, FAASLD
    Faculty
    Nothing to Disclose

    Robert J. Fontana, MD, FAASLD
    Faculty
    Scientific Consulting: Alynam Pharmaceuticals
    Grants/Research Support: BMS, Gilead, Abbvie

    Julie Heimbach, MD, FAASLD
    Faculty
    Nothing to Disclose

    Laura M. Kulik, MD
    Faculty
    Nothing to Disclose

    Jennifer C. Lai, MD
    Faculty
    Scientific Consulting: Third Rock Ventures, LLC

    Michael D. Leise, MD
    Faculty
    Nothing to Disclose

    Josh Levitsky, MD, FAASLD
    Faculty
    Grants/Research Support: Novartis Scientific
    Consulting: Novartis
    Speakers Bureau: Gilead, Salix

    Michael R. Lucey, MD, FAASLD 
    Faculty
    Grant/Research Support: Abbvie, Gilead, Pharmasoluions

    Jorge A. Marrero, MD
    Faculty
    Scientific Consulting: Eisai, Grail, Exelis, Astra Zeneca

    K. Gautham Reddy, MD, FAASLD
    Faculty
    Grants/Research Support: Merck, Intercept, Genfit
    Scientific Consulting: Intercept
    Speaker's Bureau: Intercept Dova Advisory
    Committees and/or Review Panels: American College of Gastroenterology

    Philip Rosenthal, MD, FAASLD
    Faculty
    Grants/Research Support: Gilead Scientific
    Consulting: Gilead, Retrophin, Albireo

    Mark W. Russo, MD, MPH, FAASLD
    Faculty
    Speakers Bureau: Gilead, Abbvie, Intercept, Salix

    Marina G. Silveira, MD  
    Faculty
    Scientific Consulting: Conatus

    Norah Terrault, MD, MPH, FAASLD
    Faculty
    Scientific Consulting: CME, CCO Hepatitis, Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc.
    Advisory Committees or Review Panels: Merck, Intercept, Conatus, Dova
    Grant/Research Support: AbbVie, Eisai, Gilead, BMS, Merck, Allergan, Biotest
    Royalties: UpToDate

    Lisa B. VanWagner, MD, MSc
    Faculty
    Grants/Research Support: Advanced MR Analytics (AMRA) Medical

    Maintenance of Certification Committee

    Oren K. Fix, MD, MSc, FAASLD
    Chair
    Nothing to disclose

    Mark W. Russo, MD, MPH, FAASLD
    Vice-Chair
    Commercial Speaker's Bureau: Gilead, Abbvie,Intercept, Salix

    Raymond T. Chung, MD, FAASLD
    Board Liaison
    Research Grants: Abbvie, Gilead Sciences, Boehringer Ingelheim

    Curtis K. Argo, MD, MS, FAASLD
    Member
    Nothing to disclose

    Steven K. Herrine, MD, FAASLD
    Member
    Research Grants: Gilead, BMS, Galectin, Interecept 
    Leadership in related society: Board, Committee, Journal: ABIM - Chair, Transplant Hepatology Test Committee

    Vandana Khungar, MD, MSc
    Member
    Nothing to disclose

    Ayman A. Koteish, MD, FAASLD
    Member
    Nothing to disclose

    Smruti R. Mohanty, MD, MS
    Member
    Advisory Board: Gilead science, Abbvie, Merck, Bristol Meyers Squib and Intercept
    Leadership in related society: Board, Committee, Journal: Publications Committee, American College of Gastroenterology (2009- Present) Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology

    Heather M. Patton, MD, FAASLD
    Member
    Nothing to disclose

    K. Gautham Reddy, MD, FAASLD
    Member
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept, Gilead
    Research Grants: Merck Intercept Genfit
    Commercial Speaker's Bureau: Intercept
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of;

    Grace L. Su, MD, FAASLD
    Member
    Company: Management Position

    Ryan M. Taylor, MD
    Member
    Commercial Speaker's Bureau: Merck, Inc., Abbvie, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb

    Helen S. Te, MD, FAASLD
    Member
    Research Grants: Conatus Pharmaceuticals, Abbvie, Gilead Sciences
    Advisory Board: Gilead Sciences,Intercept Pharmaceuticals

    Debra Guss, RN, NP-C, ACRN
    Associate
    Nothing to disclose

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

    Training and Workforce Committee

    K. Gautham Reddy, MD, FAASLD
    Chair
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology;
    Research Grants: Merck Intercept Genfit; Commercial Speaker's Bureau: Intercept Dova; Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept

    Raymond T. Chung, MD, FAASLD
    Board Liaison
    Research Grants: BMS, Roche,Gilead Sciences, Abbvie, Boehringer Ingelheim

    Christopher L. Bowlus, MD, FAASLD
    Member
    Research Grants: Gilead Biosciences, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Takeda Pharmaceuticals, NGM Biosciences, GlaxoSmithKline, Merck, BristolMyerSquibb, TARGET Pharmasolutions, Genkyotex, Allergan, JKB Taiwan Pharmaceuticals
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept Pharmaceuticals, GlaxoSmithKline, BristolMyersSquibb, Conatus, Patara, Eli Lilly

    Michael F. Chang, MD, MSc, FAASLD
    Member
    Nothing to disclose

    Hari S. Conjeevaram, MD, MS
    Member
    Nothing to disclose

    Amy Feldman, MD
    Member
    Nothing to disclose

    Aparna Goel, MD
    Member
    Nothing to disclose

    Seth J. Karp, MD
    Member
    Nothing to disclose

    Michael D. Leise, MD
    Member
    Nothing to disclose

    Sylvia M. Lempit, MSN
    Associate Member
    Nothing to disclose

    Michelle Long, MD
    Member
    Research Grants: Echosens

    Ian R. Schreibman, MD
    Member
    Nothing to disclose

    Jessica Davis, MD
    Trainee
    Nothing to disclose

    Omar Y. Mousa, MD
    Trainee
    Nothing to disclose

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

    Janeil Klett
    Staff Liaison
    Nothing to disclose

  • Cardiac Risk in Liver Transplantation: Getting to the “Heart” of the Matter

    Product not yet rated Contains 1 Component(s) Recorded On: 09/10/2018

    Webinar hosted by the Cardiopulmonary Affinity group September 10, 2018.

    The overall objective of this activity is to address the epidemiology, risk factors and key challenges in the evaluation and management of cardiovascular disease in liver transplant candidates. In particular, we will discuss the evolving role of cirrhotic cardiomyopathy as a marker of ongoing cardiac injury.  

    Lisa VanWagner (Moderator)

    Dr. Lisa VanWagner is an Assistant Professor of Medicine and Preventive Medicine in the Division Gastroenterology & Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.  She is board certified in Transplant Hepatology.  Her laboratory utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Her research group developed the first simple scoring model (CAR-OLT score) — accessible via web or smartphone apps — which enables healthcare providers, caregivers and patients to estimate 1-year risk for cardiovascular complications after liver transplantation.

    Sam Lee (Moderator)

    Mario Altieri

    Dr. Mario Altieri is currently the medical director of the liver transplant program at the University Hospital Center in Caen, France since November, 2012. He did his Fellowship in intensive care medicine and Fellowship in multiple organ transplantation (liver, kidney and pancreas) at Strasbourg University France Hospital, University Center Hospital  HUC. He was the Chief of residency in Internal Medicine Cordoba, Argentina (Specialist certified NUCA) and was professor in intensive care medicine catholic University of Cordoba from 2000 to 2002.

    Manhal Izzy

    Dr. Manhal Izzy is a transplant hepatologist and an assistant professor at Vanderbilt University School of Medicine. He is a member of the educational committee of the International Liver Transplantation Society (ILTS). His research focuses on cardiovascular outcomes in patients with liver disease.

  • Implications of the Hepatitis C Epidemic on Women & Children

    Contains 1 Component(s) Recorded On: 09/07/2018

    Webinar hosted by the Hepatitis C Special interest group September 7, 2018.

    Chronic hepatitis C infection remains a major public health burden with substantial morbidity and mortality. In this program, expert hepatologists will provide a state-of-the-art update on the evolving epidemiology, natural history, and evidence-based management of hepatitis C infection in women of child-bearing age, pregnancy, and children.

    Nancy S. Reau

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

     

    Tatyana Kushner

    Tatyana Kushner, MD, MSCE, is Assistant Professor in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York. She completed her medical school and internal medicine training at Mount Sinai School of Medicine, a fellowship in gastroenterology and a masters in clinical epidemiology at the University of Pennsylvania, and a fellowship in transplant hepatology at the University of California, San Francisco (UCSF). Her research focuses on both epidemiologic and patient-centered outcomes in viral hepatitis, with an emerging focus in the area of women’s health and pregnancy care, and the goal of developing and studying interventions to improve clinical outcomes in this patient population. She has recently established a Women's Liver Clinic at Mount Sinai in order to enhance the diagnosis and management of liver disease during pregnancy and post-delivery, particularly of hepatitis B and hepatitis C. 

     

    Karen Murray

    Dr. Karen Murray is board certified in pediatric gastroenterology and pediatric transplant hepatology. In addition to providing clinical care in gastroenterology, hepatology and transplantation, she has an active clinical research program. Her main focus is childhood liver disease, especially the treatment of hepatitis B and C viral infections, non-alcoholic fatty liver disease and cholestatic liver diseases in childhood. Murray is a professor of pediatrics at University of Washington School of Medicine and past president of Seattle Children’s medical staff. She is on the steering committees of three National Institute of Diabetes and Digestive and Kidney Diseases clinical research networks related to her research.

    Joseph K. Lim (Moderator)

    Joseph K. Lim, MD, FAASLD is a Professor of Medicine in the Section of Digestive Diseases and Yale Liver Center at Yale University School of Medicine in New Haven, CT where he serves as Director of the Viral Hepatitis Program.  He runs an active outcomes research and clinical trials program addressing viral hepatitis and fatty liver disease.  He is a member of the steering committee for the AASLD HCV SIG.

     

    Dawn S. Harrison (Moderator)

    Dawn S. Harrison is a Family Nurse Practitioner specializing in Gastroenterology and Hepatology at The University of North Carolina Medical Center, Chapel Hill, North Carolina. She completed her Bachelor's of Science degree in Nursing from Radford University in Radford, Virginia and then earned her Master's of Science in Nursing as a Family Nurse Practitioner at Graceland University in Independence, Missouri.  Her Doctoral of Nursing Practice degree was acquired from The University of Alabama in Tusculoosa, Alabama. She holds a national certification with the American Nurses Credentialing Center (ANCC) as Family Nurse Practitioner. 

  • Unraveling the New UNOS Liver Allocation Policy

    Contains 1 Component(s) Recorded On: 09/04/2018

    Webinar hosted by the Liver Transplantation and Surgery Special Interest Group and Liver Transplantation Journal September 4, 2018.

    The new UNOS organ allocation policy is scheduled to go into effect in December 2018. Work your way through the changes and challenges with the Chair of the AASLD Liver Transplantation SIG and Editor-in-Chief of Liver Transplantation in this first of a series of webinars brought to you by a collaboration of the SIG and journal. 

    Paul Martin (Moderator)

    Paul Martin MD, FAASLD is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, USA. He is a native of Dublin, Ireland, where he graduated from medical school at University College, Dublin. He specialized in internal medicine and gastroenterology, training initially in Dublin and subsequently in Canada. He trained in hepatology as a Medical Staff Fellow in the Liver Unit, NIH, Maryland, USA. He is Editor-in Chief of Liver Transplantation and Editor of Handbook of Liver Disease. He was previously a Councilor for AST of the American Society of Transplant. He has had a long standing interest in viral hepatitis and organ transplant. 

    Timucin Taner

    Dr. Taner is a transplant surgeon, and surgical director of liver transplantation at Mayo Clinic, Rochester. He is a member of the AASLD Surgery and Liver Transplantation Committee, and currently serves as the chair of the Liver Transplantation SIG Education Subcommittee.

    James Trotter

    Dr. James Trotter is currently the medical director of liver transplantation at Baylor University Medical Center. He is also the principal investigator of the Living donor liver transplant Cohort Study at the National Institutes of Health. Dr. Trotter is the associate editor of the Liver Transplantation journal.

  • Portal Hypertension SIG: Critical Review of Invasive Interventions in Patients with Portal Hypertension

    Contains 9 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Join international portal hypertension experts for a critical review of several invasive interventions performed in patients with the disease. This session will look at potential situations that may interfere with the accuracy and reproducibility of hepatic venous pressure gradient and portal pressure gradient measurements in the course of TIPS. It will also discuss recommendations for standardizing the procedure. Attendees will hear a review of invasive procedures used to diagnose and treat cardiofundal and ectopic varices as well as new therapeutic strategies to solve portal hypertension in patients — both children and adults — with portal cavernoma. Finally, the session will review the potential role of splenectomy or spleen embolization in the treatment of hypersplenism and of the closing or reduction of TIPS or large portocollateral shunts in patients with severe refractory hepatic encephalopathy.

    Juan C. Garcia-Pagan

    Zachary Henry

    Puneeta Tandon

    Frederik Nevens

    Riccardo A. Superina

    Riad Salem

    Wael E. Saad

  • Basic Research Workshop

    Product not yet rated Contains 9 Component(s) Recorded On: 11/13/2016

    AASLD's Basic Research Workshop presented at The Liver Meeting® 2016.

    This workshop will focus on how inducible pluripotent stem cells (iPSCs) can be used to produce liver cells and organoids. These are exciting new tools for experimental hepatology and hold great promise for clinical hepatology. The generation of iPSC-derived liver cells enables studies of the pathophysiology of several human conditions and to explore the effects of new drugs and treatment following a personalized medicine approach. iPSCs can also give rise to multicellular liver organoids with the potential to recapitulate the cellular ecosystem of a human liver, maintain the inter-cellular relationships, and reproduce models of liver disease as experimental models and potential organ-replacement strategies.

    Mario Strazzabosco

    Jorge A. Bezerra

    Stephen A. Duncan

    Takanori Takebe

    Holger Willenbring

    Romina Fiorotto

    Andrew A. Wilson

  • Clinical Hepatology Update 2017

    Product not yet rated Contains 26 Component(s) Recorded On: 06/03/2017

    This course offers didactic lectures in 6 topic areas relevant to mid-level hepatology professionals.

    The 2017 Clinical Hepatology Course is a prime opportunity for hepatology professionals to stay updated on the state-of-the-art management of liver disease. Presentations will offer clinically relevant insights on many aspects in patient care in liver disease, and a chance to discuss controversies commonly seen in clinical practice with key leaders in the field.

    This 1 1/2 day course will offer didactic lectures in 6 topic areas relevant to mid-level hepatology professionals. A breakout session titled Preventative Health Strategies in the Outpatient Management of Cirrhosis will feature a small, interactive discussion with session organizers and networking opportunities with other attendees.

    K. R. Reddy

    Jayant A. Talwalker

    Frank Lammert

    Christopher L. Bowlus

    Bernd Schnabl

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

    Michael B. Fallon

    Juan G. Abraldes

    Ram M. Subramanian

    Michael R. Lucey

    Kathleen E. Corey

    Natalie J. Torok

    R. Todd Stravitz

    Michael L. Schilsky

    Patrick S. Kamath

    Hashem B. El-Serag

    Saul J. Karpen

    Tram T. Tran

    Timothy J. Davern

  • Clinical Practice SIG: Managing and Growing a Hepatology Clinical Practice

    Product not yet rated Contains 10 Component(s) Recorded On: 11/11/2016

    AASLD's Clinical Practice SIG presented at The Liver Meeting® 2016.

    As the practice of hepatology has matured over the past decade many AASLD members have successfully developed or transitioned to community-based hepatology practices in one of three major areas: a community based health care system, a multi-speciality group practice or a hepatology-only medical practice. This workshop will bring together hepatologists, practice administrators, lawyers with medical practice speciality who work in these environments to share the medical, financial and legal models they utilize to develop successful, rewarding and financially feasible community-based hepatology practices.

    Marcelo Kugelmas

    David E. Bernstein

    Stephen A. Harrison

    Victor R. Araya

    Mitchell L. Shiffman

    Mitchell A. Mah'moud

    Tarek I. Hassanein